Clinical Trial Update: Randomized Amifostine For SCCHN [Phase 2]

View source ↗

Summary

Phase 2 randomized trial of amifostine (Ethyol) to mitigate chemotherapy- and radiotherapy-related toxicities (mucositis, xerostomia) in head and neck squamous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ETHYOL (Amifostine)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chemotherapeutic Agent Toxicity, Head and Neck Cancer | Phase 2 | Status: COMPLETED